Article of the day, September 9th, suggested by the Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn:

“Article of the day! Suggest by the Immune Oncology Research Institute.

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

Authors: John V Reynolds, Shaun R Preston, Brian O’Neill, Prof Maeve A Lowery, Lene Baeksgaard, Thomas Crosby, Moya Cunningham, Sinead Cuffe, Gareth O Griffiths, Imelda Parker, Signe Lenora Risumlund, Rajarshi Roy, Stephen Falk, Prof George B Hanna, Frederick R Bartlett, Alberto Alvarez-Iglesias, Michael P Achiam, Prof Magnus Nilsson, Prof Guillaume Piessen, Narayanasamy Ravi, Prof Dermot O’Toole, Ciaran Johnston, Prof Raymond S McDermott, Richard C Turkington, Shajahan Wahed, Sharmila Sothi, Hugo Ford, Martin S Wadley, Derek Power.

Author Affiliations: Cancer Trials Ireland ,St James’s Hospital Dublin, Royal Surrey NHS Foundation Trust, Velindre N H S Trust, Southampton Clinical Trials Unit, Hull University Teaching Hospitals NHS Trust, University Hospitals Bristol and Weston NHS Foundation Trust, Imperial College Healthcare NHS Trust, Portsmouth Hospitals University NHS Trust, Belfast Health and Social Care Trust, Worcestershire Acute Hospitals NHS Trust, et al.

Source: Immune Oncology Research Institute/LinkedIn

Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.

Other posts featuring Immune Oncology Research Institute on OncoDaily.